SCHEMBL2397450

SCHEMBL2397450

COc1ccc(CCc2nnc(-c3ccc4[nH]cnc4c3)o2)cc1OC

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
QPCT Q16769 12/20 0.85
QPCTL Q9NXS2 3/20 0.71
HPGD P15428 4/20 0.53
TSHR P16473 3/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
POLB P06746 2/20 0.53
KDM4E B2RXH2 2/20 0.53
ALDH1A1 P00352 2/20 0.53
MAPT P10636 2/20 0.53
HSD17B10 Q99714 2/20 0.53
LMNA P02545 2/20 0.51
TP53 P04637 1/20 0.51
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
TLR9 Q9NR96 1/20 0.45
TLR8 Q9NR97 1/20 0.45
TLR7 Q9NYK1 1/20 0.45
USP2 O75604 1/20 0.44
MAPK1 P28482 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2397750 0.91 QPCTL (0.85) QPCTQPCTLHPGDTSHRSMN1; SMN2
SCHEMBL2396677 0.90 QPCT (0.68) QPCTQPCTLHPGDTSHRSMN1; SMN2
SCHEMBL2397238 0.82 QPCT (0.59) QPCTQPCTLHPGDTSHRSMN1; SMN2
SCHEMBL2397644 0.82 QPCT (0.85) QPCTQPCTLHPGDTSHRKDM4E
SCHEMBL2397607 0.81 QPCT (0.82) QPCTQPCTL
SCHEMBL2397493 0.81 QPCT (0.61) QPCTQPCTL
SCHEMBL2398221 0.81 QPCT (0.85) QPCTQPCTLSMN1; SMN2KDM4EALDH1A1
SCHEMBL2398712 0.80 QPCT (0.62) QPCTQPCTLHPGDTSHRSMN1; SMN2
SCHEMBL2413629 0.79 QPCT (0.85) QPCTQPCTLTSHRSMN1; SMN2KDM4E
SCHEMBL2395058 0.79 QPCT (0.84) QPCTQPCTL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9181233-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2015-11-10 US disclosed
US-9181233-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2015-11-10 US disclosed
US-9181233-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2015-11-10 US disclosed
US-20110224259-A1 NOVEL INHIBITORS PROBIODRUG AG (DE) 2011-09-15 US disclosed
US-20110224259-A1 NOVEL INHIBITORS PROBIODRUG AG (DE) 2011-09-15 US disclosed
US-20110224259-A1 NOVEL INHIBITORS PROBIODRUG AG (DE) 2011-09-15 US disclosed
WO-2011107530-A2 NOVEL INHIBITORS PROBIODRUG AG (DE) 2011-09-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224259-A1 NOVEL INHIBITORS QPCT, GLUL, GLS QPCT 1/4885QPCTL 5/4885HPGD 210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.